Table 2 Diagnostic performance of biomarker combination panels for PDA in cohort B.
Biomarker panel | AUROC (95% CI) | F1 score (95% CI) | Accuracy (95% CI) | SN (recall) (95% CI) | SP (95% CI) | PPV (precision) (95% CI)* | NPV (95% CI)* |
|---|---|---|---|---|---|---|---|
All-stage PDA vs. healthy control | |||||||
CA19-9, GDF15, suPAR | 0.977 (0.954–0.991) | 0.940 (0.904–0.971) | 0.908 (0.854–0.954) | 0.950 (0.902–0.986) | 0.767 (0.610–0.915) | 0.931 (0.888–0.976) | 0.821 (0.661–0.948) |
CA19-9, GDF15, IL-8 | 0.964 (0.941–0.990) | 0.955 (0.928–0.983) | 0.931 (0.888–0.973) | 0.960 (0.924-1.000) | 0.833 (0.702–0.962) | 0.950 (0.907–0.990) | 0.862 (0.765-1.000) |
IL-8, GDF15, suPAR | 0.989 (0.972–0.997) | 0.955 (0.928–0.982) | 0.930 (0.892–0.973) | 0.950 (0.901–0.981) | 0.867 (0.764–0.968) | 0.959 (0.918–0.990) | 0.838 (0.704–0.940) |
CA19-9, GDF15 | 0.920 (0.876–0.957) | 0.930 (0.897–0.958) | 0.892 (0.850–0.935) | 0.930 (0.877–0.972) | 0.767 (0.617–0.903) | 0.930 (0.877–0.970) | 0.767 (0.590–0.889) |
IL-8, GDF15 | 0.951 (0.926–0.979) | 0.926 (0.894–0.955) | 0.884 (0.834–0.927) | 0.940 (0.898–0.971) | 0.700 (0.537–0.860) | 0.913 (0.856–0.957) | 0.778 (0.667–0.902) |
IL-8, suPAR | 0.979 (0.958–0.995) | 0.949 (0.920–0.977) | 0.923 (0.881–0.966) | 0.940 (0.895–0.979) | 0.867 (0.764–0.968) | 0.959 (0.916–0.990) | 0.812 (0.680–0.930) |
CA19-9 | 0.829 (0.756–0.877) | 0.834 (0.768–0.885) | 0.746 (0.665–0.816) | 0.830 (0.747–0.890) | 0.467 (0.279–0.604) | 0.838 (0.763–0.890) | 0.451 (0.273–0.596) |
IL-8 | 0.884 (0.830–0.944) | 0.887 (0.841–0.932) | 0.831 (0.769–0.892) | 0.870 (0.811–0.940) | 0.700 (0.517–0.826) | 0.906 (0.848–0.950) | 0.617 (0.460–0.764) |
GDF15 | 0.849 (0.752–0.928) | 0.876 (0.828–0.911) | 0.807 (0.738–0.858) | 0.880 (0.812–0.932) | 0.567 (0.400-0.734) | 0.871 (0.812–0.933) | 0.586 (0.431–0.714) |
suPAR | 0.955 (0.906–0.997) | 0.956 (0.927–0.981) | 0.931 (0.892–0.969) | 0.970 (0.930–0.995) | 0.800 (0.687–0.926) | 0.942 (0.902–0.981) | 0.889 (0.761–0.987) |
HGF | 0.849 (0.775–0.930) | 0.876 (0.819–0.919) | 0.808 (0.727–0.869) | 0.880 (0.809–0.947) | 0.567 (0.378–0.726) | 0.871 (0.800-0.926) | 0.586 (0.398–0.782) |
Early-stage PDA vs. healthy control | |||||||
CA19-9, GDF15, suPAR | 0.987 (0.970–0.999) | 0.937 (0.879–0.979) | 0.917 (0.851–0.971) | 0.963 (0.908-1.000) | 0.833 (0.696–0.964) | 0.912 (0.840–0.982) | 0.926 (0.833-1.000) |
CA19-9, GDF15, IL-8 | 0.973 (0.933–0.997) | 0.952 (0.902–0.987) | 0.940 (0.881–0.982) | 0.926 (0.837–0.981) | 0.967 (0.873-1.000) | 0.980 (0.920-1.000) | 0.879 (0.740–0.973) |
IL-8, GDF15, suPAR | 0.988 (0.972–0.999) | 0.944 (0.900-0.991) | 0.929 (0.869–0.988) | 0.944 (0.892-1.000) | 0.900 (0.796-1.000) | 0.944 (0.878-1.000) | 0.900 (0.797-1.000) |
CA19-9, GDF15 | 0.916 (0.843–0.969) | 0.897 (0.816–0.958) | 0.869 (0.798–0.947) | 0.889 (0.783–0.963) | 0.833 (0.696–0.948) | 0.906 (0.835–0.974) | 0.806 (0.659–0.922) |
IL-8, GDF15 | 0.933 (0.864–0.980) | 0.887 (0.815–0.947) | 0.857 (0.779–0.929) | 0.870 (0.775–0.957) | 0.833 (0.705–0.963) | 0.904 (0.838–0.982) | 0.781 (0.623–0.922) |
IL-8, suPAR | 0.986 (0.965–0.998) | 0.953 (0.913–0.982) | 0.940 (0.887–0.976) | 0.944 (0.890-1.000) | 0.933 (0.839-1.000) | 0.962 (0.907-1.000) | 0.903 (0.777-1.000) |
CA19-9 | 0.879 (0.806–0.937) | 0.830 (0.759–0.907) | 0.786 (0.696–0.869) | 0.815 (0.728–0.910) | 0.733 (0.549–0.864) | 0.846 (0.756–0.928) | 0.688 (0.535–0.846) |
GDF15 | 0.847 (0.748–0.949) | 0.811 (0.723–0.892) | 0.750 (0.655–0.851) | 0.833 (0.705–0.936) | 0.600 (0.418–0.780) | 0.789 (0.687–0.892) | 0.667 (0.481–0.840) |
suPAR | 0.963 (0.901–0.998) | 0.955 (0.916–0.984) | 0.940 (0.893–0.976) | 0.981 (0.956-1.000) | 0.867 (0.750–0.968) | 0.930 (0.861–0.982) | 0.963 (0.900-1.000) |
HGF | 0.852 (0.741–0.935) | 0.857 (0.780–0.926) | 0.821 (0.738–0.899) | 0.833 (0.728–0.919) | 0.800 (0.677–0.927) | 0.882 (0.798–0.964) | 0.727 (0.547–0.877) |
IL-8 | 0.893 (0.831–0.949) | 0.851 (0.768–0.917) | 0.821 (0.744–0.893) | 0.796 (0.671–0.903) | 0.867 (0.754-1.000) | 0.915 (0.849-1.000) | 0.703 (0.544–0.846) |
